Common use of Restricted Use Clause in Contracts

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (Fampyra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 - Apr 12

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X Gevokizumab (Coagadex) NHSE Hereditary factor X deficiency Uveitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Gilteritinib Xospata® NHSE relapsed or refractory acute myeloid leukaemia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA642 – August 2020 Hospital Givosiran Givlaari NHSE Hepatic porphyria Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST16 - Nov 2021 BLACK Glasdegib () NHSE with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA646 – September 2020 Hospital Glatiramer (Copaxone®) NHSE Multiple Sclerosis - as per NICE TA 527 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA527 - Jun 18 Hospital Glecaprevir-pibrentasvir ▼ (Maviret® ▼) NHSE Chronic hepatitis C Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA499 - Jan 18 DM Glibenclamide (Various eg Daonil®, Euglucon®) ICB Type 2 diabetes mellitus Discontinued Medicines NICE has not issued any guidance. BLACK Gliclazide modified release (Diamicron® MR) ICB Type 2 diabetes mellitus Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII Glofitamab Columvi® NHSE Specialist indications relapsed or refractory diffuse large B- cell lymphoma after 2 or more systemic treatments Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA927 – October 2023 Hospital Glucarpidase (Voraxase) NHSE Urgent treatment of methotrexate- induced renal dysfunction in patients receiving high-dose MTX chemotherapy - as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Glucocorticoids (inc hydrocortisone, prednisolone) (Generics are available) ICB Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) - as per NICE CG 53 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG53 - Aug 07 BLACK Glucosamine (Various) ICB Osteoarthritis - as per NICE CG 177 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG177 - Feb 14 BLACK Glucosamine, Glucosamine & Chondroitin (Alateris and various) ICB Osteoarthritis Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Gluten-free foods (Various) ICB Gluten sensitive enteropathies in all patients across N+W Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Glycerol phenylbutyrate (Ravicti® 1.1 g/ml oral liquid) NHSE Urea cycle disorders (specialist use only) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing GlycoPEGylated Factor IX (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (FampyraRebinyn®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Haemophilia B Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) Glycopyrronium bromide Glycobromag ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Hyperhidrosis Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 - Apr 12.

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA29 - Sep 01 BLACK Fludarabine (Fludara®) NHSE B-cell Chronic Lymphocytic Leukaemia - 1st line treatment - as per NICE TA 119 Not commissioned. No NHS prescribing in primary or secondary care TA119 - Feb 07 ADVICE Fludroxycortide tape (previously Haelan) ICB Adjunctive therapy for chronic, localised, recalcitrant dermatoses that may respond to topical corticosteroids and particularly dry, scaling lesions Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidanceguidance BLACK Fludroxycortide tape (previously Haelan) ICB All unlicensed uses including hypertrophic scars and keloids Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Factor X Fluocinolone acetonide intravitreal implant (CoagadexIluvien®) NHSE Hereditary factor X deficiency ICB Recurrent non-infectious uveitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA590 - Jul 19 Hospital Fluocinolone acetonide intravitreal implant (Iluvien®) ICB chronic diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA953 – March 2024 Hospital Fluoride supplements - Toothpaste; dental products (Duraphat 0.619% DPF; 1.1% DPF Toothpaste) ICB Prevention of dental caries in at-risk patients (where the specialist is a dentist) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication BLACK Folic acid (assume Generics are available) ICB Secondary prevention of MI / reduce cardiovsacular risk post MI - as per NICE CG 172 - Do Not Do (Not a licensed unless statedindication). Not commissioned. No NHS prescribing in primary or secondary care CG172 - Nov 13 BLACK Folic Acid (Generics are available) Instructions for Prescriber ICB For preventing hypertensive disorders during pregnancy - as per NICE Guidance CG 107 - Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG107 - Aug 10 Hospital Factor XIII NHSE Specialist indications Fomepizole (Antizol®) ICB Methanol and ethylene glycol poisoning (Poison Centre prescribing only) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Fondaparinux sodium (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (FampyraArixtra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage unstable angina or non- ST segment elevation myocardial infarction (UA/NSTEMI) in congenital hypofibrinogenaemia or afibrinogenaemia adults for whom urgent (< 120 mins) invasive management i.e. percutaneous coronary intervention (PCI) is not indicated - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England regional network policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir CG94 - Mar 10 BLACK Fondaparinux sodium (Arixtra®) NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease Prophylaxis of venous thromboembolism in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification those undergoing major orthopaedic surgery of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis the legs - as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist serviceDoNotDo recommendation Not commissioned. No NHS prescribing in primary or secondary care TA254 NG89 - Apr 12Mar 18

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X Bevacizumab (CoagadexAvastin®) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications ICB Radiation retinopathy macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Bexarotene (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (FampyraTargretin®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin Double Red Bezafibrate (DificlirBezalip; Fibrazate) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" Not recommended for routine use CG181 - Jul 14 BLACK Bezlotoxumab (Zinplava®) ICB Treatment Prevention of mild to moderate C. recurrent clostridium difficile infection (CDIterminated appraisal) Not commissioned. No NHS prescribing in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician TA601 - Sep 19 Hospital Bictecravir (in combination with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless statedemtricitabine and tenofivir alafenamide) Instructions for Prescriber NICE Guidance Hospital Filgotinib JyselecaBiktarvy ®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only HIV Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim Bimagrumab ((BYM338)) NHSE Xxxxx Syndrome - specialist centres only Inclusion body myositis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim Bimekizumab Bimzelx® ICB active psoriatic arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA916 – October 2023 Traffic Light Classification Drug Name Brand Name Commissione r Indication (Various ▼assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Bimekizumab Bimzelx® ICB axial spondyloarthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA918 – October 2023 Hospital Bimekizumab Bimzelx® ICB moderate to severe plaque psoriasis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA723 – September 2021 Hospital Binimetinib (Mektovi®) NHSE Reduction (with encorafenib (Braftovi®)) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy adults - as per NICE TA 562 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA562 - Feb 19 BLACK Bioidentical HRT (Bioidentical hormone replacement therapy) ICB Menopausal symptoms Not commissioned. No NHS England policy prescribing in primary or secondary care NG23 - Nov 13 Hospital Biotin (vitamin H) (Qizenday®, Cerenday®, MD1003) NHSE various Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () Hospital Birch bark extract n/a NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 epidermolysis bullosa Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 HST28 – September 2023 Hospital Bivalirudin (Angiox®) ICB Treatment of ST-segment-elevation myocardial infarction - Apr 12as per NICE TA 230 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA230 - Jul 11 Hospital Blinatumomab (Blincyto®) NHSE Acute lymphoblastic leukaemia in remission with minimal residual disease activity Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA589 - Jul 19 BLACK Blinatumomab N/A NHSE previously treated Philadelphia- chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA686 – March 2021

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (Fampyra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 - Apr 12

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Heparin - Low Molecular Weight (LMWH) (Various) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Factor X Heparin - Low Molecular Weight (CoagadexLMWH) NHSE Hereditary factor X deficiency (Various) ICB Unstable angina/coronary artery disease/NSTEMI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Factor XIII HIV vaccine (HIV vaccine) NHSE Specialist indications HIV infection prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor HIV/AIDS treatments (FEIBAVarious) NHSE Specialist indications HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (Fampyra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 TA965 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 March 2024 Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays Hospital Human heterologous liver cells (Effentora®, Actiq®, Instanyl®, PecFentHHLivC) (Heparesc®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried Human Normal Immunoglobulin (HumanAragam®) (Aragam®) NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia As per National Demand Management Plan - as per BCSH guidelines NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 Human Normal Immunoglobulin (FGF1Flebogamma®) gene therapy (Flebogamma® ) NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as As per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE Xxxxx Syndrome As per National Demand Management Plan - specialist centres only NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim Human normal immunoglobulin (Various ▼Gammanorm®) (Gammanorm® ) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy As per National Demand Management Plan - as per NHS England NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) As per National Demand Management Plan - NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - Apr 12NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Intratect®) (Intratect®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (IVIg) (Privigen®) NHSE As per National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) Arimoclomol NHSE Hereditary factor X deficiency Xxxxxxx Pick disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Aripiprazole (Abilify®) ICB Moderate to severe manic episodes in adolescents with bipolar I disorder - as per NICE TA 292 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA292 - Jul 13 ADVICE Aripiprazole (Abilify®) ICB Schizophrenia and bipolar mood disorder - as per NICE CG 82 and TA 213 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG82 - Mar 09 BLACK Armour Thyroid / any unlicensed thyroid products (Armour Thyroid) ICB Any indication Not commissioned. No NHS prescribing in primary or secondary care RMOC guidance - June 2019 ADVICE Aromatase inhibitors (Various) (Various) ICB Adjuvant hormonal treatment of early oestrogen-receptor-positive breast cancer in post menopausal women - as per local protocol Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG81 - Nov 06 Hospital Arsenic trioxide (Trisenox®) NHSE Acute promyelocytic leukaemia (characterised by the presence of the t[15;17] translocation or the PML/RAR- alpha gene) in adults - as per NICE TA 526 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA526 - Jun 18 GREEN Artificial saliva or salivary stimulants (Xerotin Oral spray or other cost- effective product) ICB Xerostomia from any cause where simple measures alone have been ineffective Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII Asciminib Scemblix® NHSE Specialist indications chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA813 – August 2022 Hospital Asfotase alfa Strensiq® NHSE paediatric-onset hypophosphatasia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST23 – March 2023 Double Red Aspirin () ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG17 - May 17 Double Red Aspirin () ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG28 - May 17 Double Red Asunaprevir (with Daclatasvir) () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. Hospital Atacicept () NHSE Systemic Lupus Erythematosus (SLE) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Ataluren ▼ (FEIBATranslarna® ▼) NHSE Specialist indications Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged ≥5 years who can walk - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine HST22 - Feb 2023 Hospital Atazanavir (FampyraReyataz®) NHSE Improvement of walking HIV infection in adults combination with Multiple Sclerosis with walking disability (EDSS 4-7) other antiretroviral drugs - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue BHIVA Guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried Atazanavir and Cobicistat (Human) (Evotaz®) NHSE Treatment of haemorrhage HIV infection in congenital hypofibrinogenaemia or afibrinogenaemia combination with other antiretroviral drugs - as per BCSH BHIVA guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 Atezolizumab (FGF1) gene therapy (Tecentriq®) NHSE All indications Locally advanced or metastatic non- small-cell lung cancer after chemotherapy - as per NICE TA 520 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation TA520 - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 - Apr 12May 18

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) Arimoclomol NHSE Hereditary factor X deficiency Xxxxxxx Pick disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Aripiprazole (Abilify®) ICB Moderate to severe manic episodes in adolescents with bipolar I disorder - as per NICE TA 292 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA292 - Jul 13 ADVICE Aripiprazole (Abilify®) ICB Schizophrenia and bipolar mood disorder - as per NICE CG 82 and TA 213 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG82 - Mar 09 BLACK Armour Thyroid / any unlicensed thyroid products (Armour Thyroid) ICB Any indication Not commissioned. No NHS prescribing in primary or secondary care RMOC guidance - June 2019 ADVICE Aromatase inhibitors (Various) (Various) ICB Adjuvant hormonal treatment of early oestrogen-receptor-positive breast cancer in post menopausal women - as per local protocol Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG81 - Nov 06 Hospital Arsenic trioxide (Trisenox®) NHSE Acute promyelocytic leukaemia (characterised by the presence of the t[15;17] translocation or the PML/RAR- alpha gene) in adults - as per NICE TA 526 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA526 - Jun 18 GREEN Artificial saliva or salivary stimulants (Xerotin Oral spray or other cost- effective product) ICB Xerostomia from any cause where simple measures alone have been ineffective Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII Asciminib Scemblix® NHSE Specialist indications chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA813 – August 2022 Hospital Asfotase alfa Strensiq® NHSE paediatric-onset hypophosphatasia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST23 – March 2023 Double Red Aspirin () ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG17 - May 17 Double Red Aspirin () ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG28 - May 17 Double Red Asunaprevir (with Daclatasvir) () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. Hospital Atacicept () NHSE Systemic Lupus Erythematosus (SLE) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Ataluren ▼ (FEIBATranslarna® ▼) NHSE Specialist indications Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged ≥5 years who can walk - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine HST22 - Feb 2023 Hospital Atazanavir (FampyraReyataz®) NHSE Improvement of walking HIV infection in adults combination with Multiple Sclerosis with walking disability (EDSS 4-7) other antiretroviral drugs - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue BHIVA Guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried Atazanavir and Cobicistat (Human) (Evotaz®) NHSE Treatment of haemorrhage HIV infection in congenital hypofibrinogenaemia or afibrinogenaemia combination with other antiretroviral drugs - as per BCSH BHIVA guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 Atezolizumab (FGF1) gene therapy (Tecentriq®) NHSE All indications Locally advanced or metastatic non- small-cell lung cancer after chemotherapy - as per NICE TA 520 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation TA520 - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 - Apr 12May 18

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X Arimoclomol NHSE Xxxxxxx Pick disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Aripiprazole (CoagadexAbilify®) ICB Moderate to severe manic episodes in adolescents with bipolar I disorder - as per NICE TA 292 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA292 - Jul 13 ADVICE Aripiprazole (Abilify®) ICB Schizophrenia and bipolar mood disorder - as per NICE CG 82 and TA 213 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG82 - Mar 09 BLACK Armour Thyroid / any unlicensed thyroid products (Armour Thyroid) ICB Any indication Not commissioned. No NHS prescribing in primary or secondary care RMOC guidance - June 2019 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance ADVICE Aromatase inhibitors (Various) (Various) ICB Adjuvant hormonal treatment of early oestrogen-receptor-positive breast cancer in post menopausal women - as per local protocol Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG81 - Nov 06 Hospital Arsenic trioxide (Trisenox®) NHSE Hereditary factor X deficiency Acute promyelocytic leukaemia (characterised by the presence of the t[15;17] translocation or the PML/RAR- alpha gene) in adults - as per NICE TA 526 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA526 - Jun 18 GREEN Artificial saliva or salivary stimulants (Xerotin Oral spray or other cost-effective product) ICB Xerostomia from any cause where simple measures alone have been ineffective Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Asciminib Scemblix® NHSE chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA813 – August 2022 Hospital Asfotase alfa Strensiq® NHSE paediatric-onset hypophosphatasia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST23 – March 2023 Double Red Aspirin () ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG17 - May 17 Double Red Aspirin () ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG28 - May 17 Double Red Asunaprevir (with Daclatasvir) () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. Hospital Atacicept () NHSE Systemic Lupus Erythematosus (SLE) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Ataluren ▼ (Translarna® ▼) NHSE Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged ≥5 years who can walk - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST22 - Feb 2023 Hospital Atazanavir (Reyataz®) NHSE HIV infection in combination with other antiretroviral drugs - as per BHIVA Guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Atazanavir and Cobicistat (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (FampyraEvotaz®) NHSE Improvement of walking HIV infection in adults combination with Multiple Sclerosis with walking disability (EDSS 4-7) other antiretroviral drugs - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH BHIVA guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 Atezolizumab (FGF1) gene therapy (Tecentriq®) NHSE All indications Locally advanced or metastatic non- small-cell lung cancer after chemotherapy - as per NICE TA 520 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin TA520 - May 18 Hospital Atezolizumab (DificlirTecentriq®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation NHSE Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis TA 525 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 TA525 - Jun 18 Hospital Filgotinib () Atezolizumab Tecentriq® NHSE Paediatric indications (where adult TA available) - specialist centres only monotherapy for untreated advanced non-small-cell lung cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. TA705 – June 2021 Hospital Filgotinib JyselecaAtezolizumab Tecentriq® ICB moderately to severely active ulcerative colitis NHSE untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 TA739 – June 2022 October 2021 BLACK Atezolizumab TECENTRIQ® NHSE with carboplatin and nab-paclitaxel for untreated advanced non-squamous non- small-cell lung cancer as per TA618 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA618 - Jan 20 Hospital Filgrastim () Atezolizumab Tecentriq® NHSE Xxxxx Syndrome - specialist centres only adjuvant treatment of resected non-small cell lung cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. TA823 – October 2022 Hospital Filgrastim Atezolizumab▼ (Various Tecentriq® ▼) NHSE Reduction in the duration of neutropenia with carboplatin and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy etoposide for malignancy - as per NHS England policy untreated extensive-stage small-cell lung cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 TA638 - July 2020 Hospital Fingolimod Atezolizumab▼ (GilenyaTecentriq® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 with nab-paclitaxel for untreated PD-L1- positive, locally advanced or metastatic, triple-negative breast cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 TA639 - Apr 12July 2020 Hospital Atezolizumab▼ (Tecentriq® ▼) NHSE with bevacizumab for treating advanced or unresectable hepatocellular carcinoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA666 – December 2020

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X Bevacizumab (CoagadexAvastin®) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications ICB Radiation retinopathy macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Bexarotene (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (FampyraTargretin®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin Double Red Bezafibrate (DificlirBezalip; Fibrazate) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" Not recommended for routine use CG181 - Jul 14 BLACK Bezlotoxumab (Zinplava®) ICB Treatment Prevention of mild to moderate C. recurrent clostridium difficile infection (CDIterminated appraisal) Not commissioned. No NHS prescribing in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician TA601 - Sep 19 Hospital Bictecravir (in combination with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless statedemtricitabine and tenofivir alafenamide) Instructions for Prescriber NICE Guidance Hospital Filgotinib JyselecaBiktarvy ®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only HIV Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim Bimagrumab ((BYM338)) NHSE Xxxxx Syndrome - specialist centres only Inclusion body myositis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim Bimekizumab Bimzelx® ICB active psoriatic arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA916 – October 2023 Hospital Bimekizumab Bimzelx® ICB axial spondyloarthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA918 – October 2023 Hospital Bimekizumab Bimzelx® ICB moderate to severe plaque psoriasis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA723 – September 2021 Traffic Light Classification Drug Name Brand Name Commissione r Indication (Various ▼assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Binimetinib (Mektovi®) NHSE Reduction (with encorafenib (Braftovi®)) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy adults - as per NICE TA 562 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA562 - Feb 19 BLACK Bioidentical HRT (Bioidentical hormone replacement therapy) ICB Menopausal symptoms Not commissioned. No NHS England policy prescribing in primary or secondary care NG23 - Nov 13 Hospital Biotin (vitamin H) (Qizenday®, Cerenday®, MD1003) NHSE various Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () Hospital Birch bark extract n/a NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 epidermolysis bullosa Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 HST28 – September 2023 Hospital Bivalirudin (Angiox®) ICB Treatment of ST-segment-elevation myocardial infarction - Apr 12as per NICE TA 230 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA230 - Jul 11 Hospital Blinatumomab (Blincyto®) NHSE Acute lymphoblastic leukaemia in remission with minimal residual disease activity Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA589 - Jul 19 BLACK Blinatumomab N/A NHSE previously treated Philadelphia- chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA686 – March 2021 Hospital Blinatumomab ▼ (Blincyto® ▼) NHSE Philadelphia-chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukaemia in adults - as per NICE TA 450 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA450 - Jun 17 Hospital Blisibimod () NHSE Systemic lupus erythematosus (SLE) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Clomethiazole (Heminevrin®) PHE Community-based assisted alcohol withdrawal - as per NICE CG 115 - Do Not Do Not recommended for routine use CG115 - Feb 11 GREEN Clopidogrel (Plavix®, generics approved for use - Sept 2009) ICB Prevention of atherosclerotic events Formulary - Drugs that can be initiated by Prescriber in Primary Care TA210 - Dec 10 Hospital Factor X Clopidogrel (CoagadexPlavix®, generics approved for use - Sept 2009) NHSE Hereditary factor X deficiency ICB Prophylaxis pre-elective PCI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Clopidogrel (Plavix®, generics approved for use - Sept 2009) ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG17 - May 17 Double Red Clopidogrel (Plavix®, generics approved for use - Sept 2009) ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG28 - May 17 ADVICE Clopidogrel (with low dose aspirin) (Plavix®, generics approved for use - Sept 2009) ICB Acute Coronary Syndrome without ST- segment elevation (NSTEMI) (with aspirin) Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant responsible for the first script. TA80 - Jul 04 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance ADVICE Clopidogrel (with low dose aspirin) (Plavix®, generics approved for use - Sept 2009) ICB Post elective percutaneous coronary intervention (PCI) - bare metal stent (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of in-patient stay. NICE has not issued any guidance. ADVICE Clopidogrel (with low dose aspirin) (Plavix®, generics approved for use - Sept 2009) ICB ST-elevation myocardial infarction (STEMI) (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of in patient stay; max one month. NICE has not issued any guidance. Hospital Factor XIII Clozapine (Clozaril®, Denzapine®, Zaponex®) ICB Schizophrenia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care CG82 - Mar 09 Hospital Cobicistat ▼ (Tybost® ▼) NHSE Specialist indications Use as a booster in treatment of HIV positive adults and adolescents - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Cobimetinib ▼ (in combination with vemurafenib) (Cotellic® ▼) NHSE Unresectable or metastatic BRAF V600 mutation-positive melanoma - as per NICE TA 414 Not commissioned. No NHS prescribing in primary or secondary care TA414 - Oct 16 Hospital Co-careldopa intestinal gel (Duodopa® ▼) NHSE Severe Xxxxxxxxx'x disease inadequately controlled by other preparations - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Cochlear implants (FEIBAVarious) NHSE For children and adults with severe to profound deafness - specialist commissioned use only as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA566 - Mar 19 Double Red Codeine linctus generic ICB Cough suppressant Not recommended for routine use NICE has not issued any guidance Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance BLACK Co-enzyme Q10 (Healthcrafts, Nature's Best, Lamb, Natrahealth etc) ICB All indications - as per NICE NG 71 & CG181 Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG181 - Jul 17 BLACK Co-enzyme Q11 (Healthcrafts, Nature's Best, Lamb, Natrahealth etc) ICB All indications - as per NICE NG 71 & CG181 Do Not Do Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 GREEN Colecalciferol (Vitamin D) (Licensed Vitamin D products) ICB Treatment of vitamin D deficiency in adults and children - as per local policies Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. BLACK Colecalciferol (Vitamin D) (Various) ICB To increase adherence to statin treatment - as per NICE CG 181 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG181 - Jul 14 ADVICE Colesevelam HCl (Cholestagel®) ICB Third-line option for (unlicensed) use in bile salt malabsorption causing diarrhoea (for patients under the NNUH only) (Not a licensed indication). Formulary - Specialist indications advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist should prescribe for an initial period of 8 weeks (for new patients). NICE has not issued any guidance. Double Red Colesevelam HCl ▼ (Cholestagel® ▼) ICB Hypercholesterolaemia - as per NICE CG 181 Do Not Do Not recommended for routine use CG181 - Jul 14 Double Red Colesevelam hydrochloride (Cholestagel®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do Not recommended for routine use CG181 - Jul 14 Hospital Colestilan () NHSE Management of hyperphosphataemia in adults on renal dialysis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (Fampyra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate Colestipol hydrochloride (Lipantil®; Supralip®; CholibColestid®) ICB Prevention of CVD CVD, alone or added to a statin - as per NICE CG 181 "- Do Not Do" Do (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Double Red Colestyramine (Questran®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays Hospital Colistimethate sodium (Effentoranebulised) (Colomycin®, Actiq®, Instanyl®, PecFentPromixin®) ICB NHSE Pseudomonas lung infection in Cystic Fibrosis (Acutenew patients from 1st April 2013) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA276 - Mar 13 AMB Colistimethate sodium (Nebulised) (Colomycin®, Promixin®) ICB Ps. aeurginosa infection in non-Cystic Fibrosis bronchiectasis Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review NICE has not issued any guidance. Double Red Filibuvir Hospital Colistimethate sodium Dry Powder Inhaler (Colobreathe® Dry Powder Inhaler) NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease Pseudomonas lung infection in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis cystic fibrosis - as per NICE TA 254 276 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 TA276 - Apr 12Mar 13 DM Collagenase clostridium histolyticum (Xiapex®) ICB Dupuytren's contracture with a palpable cord in adults - as per NICE TA 459 Discontinued Medicines TA459 - Jul 17 DM Collagenase Clostridium Histolyticum (Xiapex®) ICB Peyronie’s Disease Discontinued Medicines NICE has not issued any guidance. BLACK Combination analgesics with caffeine () ICB Pain relief Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance.

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight (LMWH) (Various) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Factor XIII Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE Specialist indications HIV infection prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor HIV/AIDS treatments (FEIBAVarious) NHSE Specialist indications HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Fampridine Hormone Replacement Therapy (Fampyra®HRT) NHSE Improvement - systemic (Various) ICB Treatment of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) urinary incontinence - as per NHS England policy NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat CG171 - Nov 15 NF HRT implants (Adenuric®Various) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE diseaseHormone replacement therapy Non-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Human alpha-1 proteinase inhibitor NHSE Emphysema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – February 2021 March 2024 Hospital Filgotinib Human heterologous liver cells (HHLivC) (Heparesc®) NHSE Paediatric indications (where adult TA available) - specialist centres only Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim Human Normal Immunoglobulin (Aragam®) (Aragam®) NHSE Xxxxx Syndrome As per National Demand Management Plan - specialist centres only NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim Human Normal Immunoglobulin (Various ▼Flebogamma®) (Flebogamma®) NHSE Reduction As per National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE As per National Demand Management Plan - as per NHS England NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) As per National Demand Management Plan - NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - Apr 12NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications Bevacizumab (Avastin®) ICB Radiation retinopathy macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Bexarotene (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (FampyraTargretin®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin Double Red Bezafibrate (DificlirBezalip; Fibrazate) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" Not recommended for routine use CG181 - Jul 14 BLACK Bezlotoxumab (Zinplava®) ICB Treatment Prevention of mild to moderate C. recurrent clostridium difficile infection (CDIterminated appraisal) Not commissioned. No NHS prescribing in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician TA601 - Sep 19 Hospital Bictecravir (in combination with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless statedemtricitabine and tenofivir alafenamide) Instructions for Prescriber NICE Guidance Hospital Filgotinib JyselecaBiktarvy ®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only HIV Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim Bimagrumab ((BYM338)) NHSE Xxxxx Syndrome - specialist centres only Inclusion body myositis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim Bimekizumab Bimzelx® ICB active psoriatic arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA916 – October 2023 Hospital Bimekizumab Bimzelx® ICB axial spondyloarthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA918 – October 2023 Hospital Bimekizumab Bimzelx® ICB moderate to severe plaque psoriasis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA723 – September 2021 Hospital Binimetinib (Various ▼Mektovi®) NHSE Reduction (with encorafenib (Braftovi®)) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy adults - as per NICE TA 562 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA562 - Feb 19 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Bioidentical HRT (Bioidentical hormone replacement therapy) ICB Menopausal symptoms Not commissioned. No NHS England policy prescribing in primary or secondary care NG23 - Nov 13 Hospital Biotin (vitamin H) (Qizenday®, Cerenday®, MD1003) NHSE various Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () Hospital Birch bark extract n/a NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 epidermolysis bullosa Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 HST28 – September 2023 Hospital Bivalirudin (Angiox®) ICB Treatment of ST-segment-elevation myocardial infarction - as per NICE TA 230 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA230 - Jul 11 Hospital Blinatumomab (Blincyto®) NHSE Acute lymphoblastic leukaemia in remission with minimal residual disease activity Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA589 - Jul 19 BLACK Blinatumomab N/A NHSE previously treated Philadelphia- chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA686 – March 2021 Hospital Blinatumomab ▼ (Blincyto® ▼) NHSE Philadelphia-chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukaemia in adults - as per NICE TA 450 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA450 - Jun 17 Hospital Blisibimod () NHSE Systemic lupus erythematosus (SLE) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Boceprevir (Victrelis®) NHSE Treatment of genotype 1 chronic hepatitis C - as per NICE TA 253 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA253 - Apr 1212 Hospital Bortezomib (Velcade®) NHSE Multiple myeloma (first line) - as per NICE 228 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA228 - Jul 11

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA47 - Sep 02 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE has not issued any guidance. Guidance Hospital Factor X (Coagadex) NHSE Hereditary factor X deficiency Eptinezumab VYEPTI® ICB preventing migraine Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication TA871 – March 2023 Hospital Eptotermin alfa (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (Fampyra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Complex spinal surgery Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R Erectile dysfunction drugs (Toviaz®Various) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Erectile dysfunction - limited categories of patients under SLS for certain drugs Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 NICE has not issued any guidance. Hospital Fibrin sealants Erectile dysfunction drugs (Fibrin sealantsVarious) NHSE Haemostatic / tissue glue ICB Severe distress from erectile dysfunction seeking treatment on the NHS Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib JyselecaBLUE Erenumab Aimovig® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes Preventing migraine NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- TA682 – March 2023 2021 ADVICE Ergocalciferol / Vitamin D Injections ICB Vitamin D deficiency Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Hospital Fingolimod ▼ Eribulin (Gilenya® ▼Halaven®) NHSE Highly active relapsing remitting multiple sclerosis Locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens only when it has progressed after at least 2 chemotherapy regimens (which may include an anthracycline or a taxane, and capecitabine) - as per NICE TA 254 423 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 TA423 - Apr 12Dec 16 Hospital Eribulin (Halaven®) NHSE Treatment of locally advanced or metastatic breast cancer - as per NICE TA 423 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA423 - Dec 16 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Eribulin (Halaven®) NHSE Locally advanced or metastatic breast cancer after 1 chemotherapy regimen - as per NICE TA 515 Not commissioned. No NHS prescribing in primary or secondary care TA515 - Mar 18 BLACK Erlotinib (Tarceva®) NHSE Monotherapy for maintenance treatment of non-small-cell lung cancer - as per NICE TA 227 and NHS England policy Not commissioned. No NHS prescribing in primary or secondary care TA227 - Jun 11 Hospital Erlotinib (Tarceva®) NHSE First-line treatment of locally advanced or metastatic EGFR-TK mutation- positive non-small-cell lung cancer - as per NICE TA 258 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA258 - Jun 12 BLACK Erlotinib (Tarceva®) NHSE Treatment of non-small-cell lung cancer (NSCLC) as per NICE TA 374 - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care TA374 - Dec 15 BLACK Erlotinib (Tarceva®) NHSE Treating locally advanced or metastatic NSCLC that doesn’t test positive for the EGFR TK mutation (as per NICE TA 374) (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care TA374 - Dec 15 ADVICE Ertugliflozin (Steglatro®) ICB As monotherapy or with metformin for treating type 2 diabetes - as per NICE TA 572 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA572 - Mar 19 GREEN Ertugliflozin (Steglatro®) ICB With metformin and a depeptidyl peptidase-4 inhibitor for Type 2 diabetes Formulary - Drugs that can be initiated by Prescriber in Primary Care TA583 - Jun 19 Hospital Erythropoietin (epoetin / darbepoetin) (Various) ICB Treatment of anaemia in people with cancer having chemotherapy - as per NICE TA 323 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA323 - Nov 14 Hospital Erythropoietin / Epoetin (Eprex) ICB Treatment of transfusion-dependent anaemia in myelodysplasia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Erythropoietin / Epoetin (Eprex®, NeoRecormon ® and others) NHSE Dialysis-induced anaemia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care CG114 - Nov 11 Double Red Erythropoietin / Epoetin (Eprex®, NeoRecormon ® and others) ICB Anaemia in renal failure pre-dialysis. Not recommended for routine use NG8 - Jun 15

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X Double Red Clomethiazole (Coagadex) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (FampyraHeminevrin®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4PHE Community-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol based assisted alcohol withdrawal - as per NICE TA 164 CG 115 - Do Not Do Not recommended for routine use CG115 - Feb 11 GREEN Clopidogrel (Plavix®, generics approved for use - Sept 2009) ICB Prevention of atherosclerotic events Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 TA210 - Dec 08 10 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted Clopidogrel (Plavix®, generics approved for use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®- Sept 2009) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl IProphylaxis pre-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care elective PCI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol Clopidogrel (FeraccruPlavix®) (Feraccru®, generics approved for use - Sept 2009) ICB Treatment Primary prevention of iron-deficiency anaemia CVD in adults (see separate Red entry regarding use in IBD) T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol NG17 - May 17 Double Red Clopidogrel (FeraccruPlavix®) (Feraccru®, generics approved for use - Sept 2009) ICB Treatment Primary prevention of iron-deficiency anaemia CVD in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital T1 or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia T2 Diabetes - as per BCSH guidelines Restricted NG17 and NG 28 Do Not Do's Not recommended for routine use – Prescribing to remain NG28 - May 17 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance ADVICE Clopidogrel (with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 low dose aspirin) (FGF1) gene therapy () NHSE All indications Restricted Plavix®, generics approved for use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®- Sept 2009) ICB Treatment of mild to moderate C. difficile infection Acute Coronary Syndrome without ST- segment elevation (CDINSTEMI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy (with aspirin) Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant responsible for the first script. TA80 - Jul 04 ADVICE Clopidogrel (with low dose aspirin) (Plavix®, generics approved for use - Sept 2009) ICB Post elective percutaneous coronary intervention (PCI) - bare metal stent (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of in-patient stay. NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication ADVICE Clopidogrel (assume with low dose aspirin) (Plavix®, generics approved for use - Sept 2009) ICB ST-elevation myocardial infarction (STEMI) (Not a licensed unless stated) Instructions indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for Prescriber an initial period of in patient stay; max one month. NICE Guidance has not issued any guidance. Hospital Filgotinib JyselecaClozapine (Clozaril®, Denzapine®, Zaponex®) ICB Moderate to severe rheumatoid arthritis Schizophrenia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 CG82 - Mar 09 Hospital Filgotinib Cobicistat ▼ () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib JyselecaTybost® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction Use as a booster in the duration treatment of neutropenia HIV positive adults and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy adolescents - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod BLACK Cobimetinib ▼ (Gilenyain combination with vemurafenib) (Cotellic® ▼) NHSE Highly active relapsing remitting multiple sclerosis Unresectable or metastatic BRAF V600 mutation-positive melanoma - as per NICE TA 254 414 Not commissioned. No NHS prescribing in primary or secondary care TA414 - Oct 16 Hospital Co-careldopa intestinal gel (Duodopa® ▼) NHSE Severe Xxxxxxxxx'x disease inadequately controlled by other preparations - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 NICE has not issued any guidance. Hospital Cochlear implants (Various) NHSE For children and adults with severe to profound deafness - Apr 12specialist commissioned use only as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA566 - Mar 19 Double Red Codeine linctus generic ICB Cough suppressant Not recommended for routine use NICE has not issued any guidance Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Co-enzyme Q10 (Healthcrafts, Nature's Best, Lamb, Natrahealth etc) ICB All indications - as per NICE NG 71 & CG181 Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG181 - Jul 17 BLACK Co-enzyme Q11 (Healthcrafts, Nature's Best, Lamb, Natrahealth etc) ICB All indications - as per NICE NG 71 & CG181 Do Not Do Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 GREEN Colecalciferol (Vitamin D) (Licensed Vitamin D products) ICB Treatment of vitamin D deficiency in adults and children - as per local policies Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. BLACK Colecalciferol (Vitamin D) (Various) ICB To increase adherence to statin treatment - as per NICE CG 181 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG181 - Jul 14 ADVICE Colesevelam HCl (Cholestagel®) ICB Third-line option for (unlicensed) use in bile salt malabsorption causing diarrhoea (for patients under the NNUH only) (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist should prescribe for an initial period of 8 weeks (for new patients). NICE has not issued any guidance. Double Red Colesevelam HCl ▼ (Cholestagel® ▼) ICB Hypercholesterolaemia - as per NICE CG 181 Do Not Do Not recommended for routine use CG181 - Jul 14 Double Red Colesevelam hydrochloride (Cholestagel®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do Not recommended for routine use CG181 - Jul 14 Hospital Colestilan () NHSE Management of hyperphosphataemia in adults on renal dialysis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Colestipol hydrochloride (Colestid®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Double Red Colestyramine (Questran®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Colistimethate sodium (nebulised) (Colomycin®, Promixin®) NHSE Pseudomonas lung infection in Cystic Fibrosis (new patients from 1st April 2013) - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA276 - Mar 13 AMB Colistimethate sodium (Colomycin®, Promixin®) ICB Ps. aeurginosa infection in non-Cystic Fibrosis bronchiectasis Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review NICE has not issued any guidance. (Nebulised) Hospital Colistimethate sodium Dry Powder Inhaler (Colobreathe® Dry Powder Inhaler) NHSE Pseudomonas lung infection in cystic fibrosis - as per NICE TA 276 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA276 - Mar 13 DM Collagenase clostridium histolyticum (Xiapex®) ICB Dupuytren's contracture with a palpable cord in adults - as per NICE TA 459 Discontinued Medicines TA459 - Jul 17

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidanceTA47 - Sep 02 Hospital Eptinezumab VYEPTI® ICB preventing migraine Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA871 – March 2023 Hospital Factor X Eptotermin alfa (Coagadex) NHSE Hereditary factor X deficiency Complex spinal surgery Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance GREEN Erectile dysfunction drugs (Various) ICB Erectile dysfunction - limited categories of patients under SLS for certain drugs Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Factor XIII NHSE Specialist indications Erectile dysfunction drugs (Various) ICB Severe distress from erectile dysfunction seeking treatment on the NHS Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (Fampyra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab VabysmoBLUE Erenumab Aimovig® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes Preventing migraine NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- TA682 – March 2023 2021 Hospital Fingolimod ▼ Eribulin (Gilenya® ▼Halaven®) NHSE Highly active relapsing remitting multiple sclerosis Locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens only when it has progressed after at least 2 chemotherapy regimens (which may include an anthracycline or a taxane, and capecitabine) - as per NICE TA 254 423 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 TA423 - Apr 12Dec 16 Hospital Eribulin (Halaven®) NHSE Treatment of locally advanced or metastatic breast cancer - as per NICE TA 423 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA423 - Dec 16 BLACK Eribulin (Halaven®) NHSE Locally advanced or metastatic breast cancer after 1 chemotherapy regimen - as per NICE TA 515 Not commissioned. No NHS prescribing in primary or secondary care TA515 - Mar 18 BLACK Erlotinib (Tarceva®) NHSE Monotherapy for maintenance treatment of non-small-cell lung cancer - as per NICE TA 227 and NHS England policy Not commissioned. No NHS prescribing in primary or secondary care TA227 - Jun 11 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Erlotinib (Tarceva®) NHSE First-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer - as per NICE TA 258 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA258 - Jun 12 BLACK Erlotinib (Tarceva®) NHSE Treatment of non-small-cell lung cancer (NSCLC) as per NICE TA 374 - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care TA374 - Dec 15 BLACK Erlotinib (Tarceva®) NHSE Treating locally advanced or metastatic NSCLC that doesn’t test positive for the EGFR TK mutation (as per NICE TA 374) (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care TA374 - Dec 15 ADVICE Ertugliflozin (Steglatro®) ICB As monotherapy or with metformin for treating type 2 diabetes - as per NICE TA 572 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA572 - Mar 19 GREEN Ertugliflozin (Steglatro®) ICB With metformin and a depeptidyl peptidase-4 inhibitor for Type 2 diabetes Formulary - Drugs that can be initiated by Prescriber in Primary Care TA583 - Jun 19 Hospital Erythropoietin (epoetin / darbepoetin) (Various) ICB Treatment of anaemia in people with cancer having chemotherapy - as per NICE TA 323 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA323 - Nov 14 Hospital Erythropoietin / Epoetin (Eprex) ICB Treatment of transfusion-dependent anaemia in myelodysplasia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Erythropoietin / Epoetin (Eprex®, NeoRecormon® and others) NHSE Dialysis-induced anaemia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care CG114 - Nov 11 Double Red Erythropoietin / Epoetin (Eprex®, NeoRecormon® and others) ICB Anaemia in renal failure pre-dialysis. Not recommended for routine use NG8 - Jun 15 BLACK Esketamine Spravato® ICB nasal spray for treatment-resistant depression Not commissioned. No NHS prescribing in primary or secondary care TA854 – December 2022

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Factor XIII NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Double Red Clomethiazole (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (FampyraHeminevrin®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4PHE Community-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol based assisted alcohol withdrawal - as per NICE TA 164 CG 115 - Do Not Do Not recommended for routine use CG115 - Feb 11 GREEN Clopidogrel (Plavix®, generics approved for use - Sept 2009) ICB Prevention of atherosclerotic events Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 TA210 - Dec 08 10 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted Clopidogrel (Plavix®, generics approved for use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®- Sept 2009) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl IProphylaxis pre-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care elective PCI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol Clopidogrel (FeraccruPlavix®) (Feraccru®, generics approved for use - Sept 2009) ICB Treatment Primary prevention of iron-deficiency anaemia CVD in adults (see separate Red entry regarding use in IBD) T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol NG17 - May 17 Double Red Clopidogrel (FeraccruPlavix®) (Feraccru®, generics approved for use - Sept 2009) ICB Treatment Primary prevention of iron-deficiency anaemia CVD in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital T1 or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia T2 Diabetes - as per BCSH guidelines Restricted NG17 and NG 28 Do Not Do's Not recommended for routine use – Prescribing to remain NG28 - May 17 ADVICE Clopidogrel (with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 low dose aspirin) (FGF1) gene therapy () NHSE All indications Restricted Plavix®, generics approved for use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®- Sept 2009) ICB Treatment of mild to moderate C. difficile infection Acute Coronary Syndrome without ST- segment elevation (CDINSTEMI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy (with aspirin) Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant responsible for the first script. TA80 - Jul 04 ADVICE Clopidogrel (with low dose aspirin) (Plavix®, generics approved for use - Sept 2009) ICB Post elective percutaneous coronary intervention (PCI) - bare metal stent (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of in-patient stay. NICE has not issued any guidance. ADVICE Clopidogrel (with low dose aspirin) (Plavix®, generics approved for use - Sept 2009) ICB ST-elevation myocardial infarction (STEMI) (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of in patient stay; max one month. NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib JyselecaClozapine (Clozaril®, Denzapine®, Zaponex®) ICB Moderate to severe rheumatoid arthritis Schizophrenia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 CG82 - Mar 09 Hospital Filgotinib Cobicistat ▼ () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib JyselecaTybost® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction Use as a booster in the duration treatment of neutropenia HIV positive adults and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy adolescents - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod BLACK Cobimetinib ▼ (Gilenyain combination with vemurafenib) (Cotellic® ▼) NHSE Highly active relapsing remitting multiple sclerosis Unresectable or metastatic BRAF V600 mutation-positive melanoma - as per NICE TA 254 414 Not commissioned. No NHS prescribing in primary or secondary care TA414 - Oct 16 Hospital Co-careldopa intestinal gel (Duodopa® ▼) NHSE Severe Xxxxxxxxx'x disease inadequately controlled by other preparations - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 NICE has not issued any guidance. Hospital Cochlear implants (Various) NHSE For children and adults with severe to profound deafness - Apr 12specialist commissioned use only as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA566 - Mar 19 Double Red Codeine linctus generic ICB Cough suppressant Not recommended for routine use NICE has not issued any guidance BLACK Co-enzyme Q10 (Healthcrafts, Nature's Best, Lamb, Natrahealth etc) ICB All indications - as per NICE NG 71 & CG181 Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG181 - Jul 17 BLACK Co-enzyme Q11 (Healthcrafts, Nature's Best, Lamb, Natrahealth etc) ICB All indications - as per NICE NG 71 & CG181 Do Not Do Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 GREEN Colecalciferol (Vitamin D) (Licensed Vitamin D products) ICB Treatment of vitamin D deficiency in adults and children - as per local policies Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. BLACK Colecalciferol (Vitamin D) (Various) ICB To increase adherence to statin treatment - as per NICE CG 181 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance ADVICE Colesevelam HCl (Cholestagel®) ICB Third-line option for (unlicensed) use in bile salt malabsorption causing diarrhoea (for patients under the NNUH only) (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist should prescribe for an initial period of 8 weeks (for new patients). NICE has not issued any guidance. Double Red Colesevelam HCl ▼ (Cholestagel® ▼) ICB Hypercholesterolaemia - as per NICE CG 181 Do Not Do Not recommended for routine use CG181 - Jul 14 Double Red Colesevelam hydrochloride (Cholestagel®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do Not recommended for routine use CG181 - Jul 14 Hospital Colestilan () NHSE Management of hyperphosphataemia in adults on renal dialysis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Colestipol hydrochloride (Colestid®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Double Red Colestyramine (Questran®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Hospital Colistimethate sodium (nebulised) (Colomycin®, Promixin®) NHSE Pseudomonas lung infection in Cystic Fibrosis (new patients from 1st April 2013) - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA276 - Mar 13 AMB Colistimethate sodium (Nebulised) (Colomycin®, Promixin®) ICB Ps. aeurginosa infection in non-Cystic Fibrosis bronchiectasis Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review NICE has not issued any guidance. Hospital Colistimethate sodium Dry Powder Inhaler (Colobreathe® Dry Powder Inhaler) NHSE Pseudomonas lung infection in cystic fibrosis - as per NICE TA 276 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA276 - Mar 13 DM Collagenase clostridium histolyticum (Xiapex®) ICB Dupuytren's contracture with a palpable cord in adults - as per NICE TA 459 Discontinued Medicines TA459 - Jul 17 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA29 - Sep 01 BLACK Fludarabine (Fludara®) NHSE B-cell Chronic Lymphocytic Leukaemia - 1st line treatment - as per NICE TA 119 Not commissioned. No NHS prescribing in primary or secondary care TA119 - Feb 07 ADVICE Fludroxycortide tape (previously Haelan) ICB Adjunctive therapy for chronic, localised, recalcitrant dermatoses that may respond to topical corticosteroids and particularly dry, scaling lesions Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidanceguidance BLACK Fludroxycortide tape (previously Haelan) ICB All unlicensed uses including hypertrophic scars and keloids Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Factor X Fluocinolone acetonide intravitreal implant (CoagadexIluvien®) NHSE Hereditary factor X deficiency ICB Treatment of chronic diabetic macular oedema after inadequate response to prior therapy - pseudophakic eye only - as per NICE TA 301 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA301 - Nov 13 Hospital Fluocinolone acetonide intravitreal implant (Iluvien®) ICB Recurrent non-infectious uveitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA590 - Jul 19 BLACK Fluocinolone acetonide intravitreal implant (Iluvien®) ICB Chronic diabetic macular oedema insufficiently responsive to available therapies in an eye with a natural lens (phakic eye) Not commissioned. No NHS prescribing in primary or secondary care TA613 - Nov 2019 Hospital Fluoride supplements - Toothpaste; dental products (Duraphat 0.619% DPF; 1.1% DPF Toothpaste) ICB Prevention of dental caries in at-risk patients (where the specialist is a dentist) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication BLACK Folic acid (assume Generics are available) ICB Secondary prevention of MI / reduce cardiovsacular risk post MI - as per NICE CG 172 - Do Not Do (Not a licensed unless statedindication). Not commissioned. No NHS prescribing in primary or secondary care CG172 - Nov 13 BLACK Folic Acid (Generics are available) Instructions for Prescriber ICB For preventing hypertensive disorders during pregnancy - as per NICE Guidance CG 107 - Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG107 - Aug 10 Hospital Factor XIII NHSE Specialist indications Fomepizole (Antizol®) ICB Methanol and ethylene glycol poisoning (Poison Centre prescribing only) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor Fondaparinux sodium (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (FampyraArixtra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage unstable angina or non- ST segment elevation myocardial infarction (UA/NSTEMI) in congenital hypofibrinogenaemia or afibrinogenaemia adults for whom urgent (< 120 mins) invasive management i.e. percutaneous coronary intervention (PCI) is not indicated - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE Xxxxx Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England regional network policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Filibuvir () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA254 CG94 - Apr 12Mar 10